Special aspects of the clinical course and replacement therapy peculiarities in a patient with autoimmune polyglandular syndrome type 1: a clinical case

Autoimmune polyglandular syndrome type 1 (APS-1) is an extremely rare monogenic autosomal recessive disease characterized by development of multiple organ failure with predominant endocrine glands involvement. The challenges of patient management are related to low adherence to the lifelong multicom...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria G. Pavlova, Olga O. Golounina, Tatyana B. Morgunova, Natalya V. Likhodey, Marina F. Kalashnikova, Aleksandr G. Farmanov, Tamriko D. Khazaliya, Valentin V. Fadeev
Format: Article
Language:Russian
Published: MONIKI 2024-12-01
Series:Alʹmanah Kliničeskoj Mediciny
Subjects:
Online Access:https://almclinmed.ru/jour/article/viewFile/17234/1696
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841527544526929920
author Maria G. Pavlova
Olga O. Golounina
Tatyana B. Morgunova
Natalya V. Likhodey
Marina F. Kalashnikova
Aleksandr G. Farmanov
Tamriko D. Khazaliya
Valentin V. Fadeev
author_facet Maria G. Pavlova
Olga O. Golounina
Tatyana B. Morgunova
Natalya V. Likhodey
Marina F. Kalashnikova
Aleksandr G. Farmanov
Tamriko D. Khazaliya
Valentin V. Fadeev
author_sort Maria G. Pavlova
collection DOAJ
description Autoimmune polyglandular syndrome type 1 (APS-1) is an extremely rare monogenic autosomal recessive disease characterized by development of multiple organ failure with predominant endocrine glands involvement. The challenges of patient management are related to low adherence to the lifelong multicomponent therapy, high risk of complications, including pneumonia, adrenal insufficiency decompensation, necrotic colitis and other acute infectious and inflammatory diseases. Due to the rarity of this disorder, clinicians lack sufficient experience with management of such patients, which could lead to delayed medical care and patient death. Patient A., 28 years old, was followed up for 10 years in the Endocrinology clinic with the diagnosis of “Autoimmune polyglandular syndrome type 1. Mucocutaneous candidiasis. Primary hypoparathyroidism. Primary chronic adrenal insufficiency. Primary hypothyroidism. Chronic gastroduodenitis. Chronic colitis. Autoimmune alopecia.” The onset of the disease with chronic mucocutaneous candidiasis at the age below 1 year had defined the severe course of the disease, including a wide range of consequently occurring autoimmune diseases associated with recurrent episodes of decompensation of hypoparathyroidism and adrenal insufficiency, as well as the development of acute necrotic colitis at the age of 26. As an adult, the patient admitted that he had previously been insufficiently responsible and attentive to his disease and regular medication intake, with resulting episodes of adrenal insufficiency decompensation and occurrence of the symptoms related to serum calcium fluctuations. Due to abnormalities of cellular and humoral immunity, APS-1 patients are at an extremely high risk for a critical course of COVID-associated pneumonia. In 2020, the patient contracted the coronavirus infection complicated by bilateral pneumonia, followed by respiratory failure, bacterial sepsis and acute renal failure. Despite the timely hospitalization, administration of the state-of-the-art antibacterials and antifungals and all the necessary resuscitation measures, it was not possible to save his life. This clinical observation demonstrates the difficulties of therapeutic management of APS-1 patients with an early disease manifestation, who, due to severe genetically determined impaired immunity, are at high risk of death from an intercurrent infection. The combination of several chronic comorbidities and the need to take a large number of replacement treatments require an individual therapeutic approach, as well as psychological and social adaptation of the patients, starting from their childhood and throughout the whole life, taking into account the frequent psychological problems could lead to low treatment adherence. The timely diagnostics of the disease, understanding of pathophysiology and specifics of its course could contribute to increased qualityadjusted life years of APS-1 patients.
format Article
id doaj-art-ddb85e7025c74659a7c269c0c46b1036
institution Kabale University
issn 2072-0505
2587-9294
language Russian
publishDate 2024-12-01
publisher MONIKI
record_format Article
series Alʹmanah Kliničeskoj Mediciny
spelling doaj-art-ddb85e7025c74659a7c269c0c46b10362025-01-15T13:59:42ZrusMONIKIAlʹmanah Kliničeskoj Mediciny2072-05052587-92942024-12-0152634235010.18786/2072-0505-2024-52-0301005Special aspects of the clinical course and replacement therapy peculiarities in a patient with autoimmune polyglandular syndrome type 1: a clinical caseMaria G. Pavlova0https://orcid.org/0000-0001-6073-328XOlga O. Golounina1https://orcid.org/0000-0003-2320-1051Tatyana B. Morgunova2https://orcid.org/0000-0003-1500-1586Natalya V. Likhodey3https://orcid.org/0000-0002-4680-0746Marina F. Kalashnikova4https://orcid.org/0000-0002-1282-2576Aleksandr G. Farmanov5https://orcid.org/0000-0002-5700-7663Tamriko D. Khazaliya6Valentin V. Fadeev7https://orcid.org/0000-0002-3026-6315I.M. Sechenov First Moscow State Medical UniversityNational Medical Research Center for EndocrinologyI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityCity polyclinic No. 134, MoscowI.M. Sechenov First Moscow State Medical UniversityAutoimmune polyglandular syndrome type 1 (APS-1) is an extremely rare monogenic autosomal recessive disease characterized by development of multiple organ failure with predominant endocrine glands involvement. The challenges of patient management are related to low adherence to the lifelong multicomponent therapy, high risk of complications, including pneumonia, adrenal insufficiency decompensation, necrotic colitis and other acute infectious and inflammatory diseases. Due to the rarity of this disorder, clinicians lack sufficient experience with management of such patients, which could lead to delayed medical care and patient death. Patient A., 28 years old, was followed up for 10 years in the Endocrinology clinic with the diagnosis of “Autoimmune polyglandular syndrome type 1. Mucocutaneous candidiasis. Primary hypoparathyroidism. Primary chronic adrenal insufficiency. Primary hypothyroidism. Chronic gastroduodenitis. Chronic colitis. Autoimmune alopecia.” The onset of the disease with chronic mucocutaneous candidiasis at the age below 1 year had defined the severe course of the disease, including a wide range of consequently occurring autoimmune diseases associated with recurrent episodes of decompensation of hypoparathyroidism and adrenal insufficiency, as well as the development of acute necrotic colitis at the age of 26. As an adult, the patient admitted that he had previously been insufficiently responsible and attentive to his disease and regular medication intake, with resulting episodes of adrenal insufficiency decompensation and occurrence of the symptoms related to serum calcium fluctuations. Due to abnormalities of cellular and humoral immunity, APS-1 patients are at an extremely high risk for a critical course of COVID-associated pneumonia. In 2020, the patient contracted the coronavirus infection complicated by bilateral pneumonia, followed by respiratory failure, bacterial sepsis and acute renal failure. Despite the timely hospitalization, administration of the state-of-the-art antibacterials and antifungals and all the necessary resuscitation measures, it was not possible to save his life. This clinical observation demonstrates the difficulties of therapeutic management of APS-1 patients with an early disease manifestation, who, due to severe genetically determined impaired immunity, are at high risk of death from an intercurrent infection. The combination of several chronic comorbidities and the need to take a large number of replacement treatments require an individual therapeutic approach, as well as psychological and social adaptation of the patients, starting from their childhood and throughout the whole life, taking into account the frequent psychological problems could lead to low treatment adherence. The timely diagnostics of the disease, understanding of pathophysiology and specifics of its course could contribute to increased qualityadjusted life years of APS-1 patients.https://almclinmed.ru/jour/article/viewFile/17234/1696autoimmune polyglandular syndrome type 1aireautoimmune regulator geneprimary adrenal insufficiencyclinical caseadherence to treatment
spellingShingle Maria G. Pavlova
Olga O. Golounina
Tatyana B. Morgunova
Natalya V. Likhodey
Marina F. Kalashnikova
Aleksandr G. Farmanov
Tamriko D. Khazaliya
Valentin V. Fadeev
Special aspects of the clinical course and replacement therapy peculiarities in a patient with autoimmune polyglandular syndrome type 1: a clinical case
Alʹmanah Kliničeskoj Mediciny
autoimmune polyglandular syndrome type 1
aire
autoimmune regulator gene
primary adrenal insufficiency
clinical case
adherence to treatment
title Special aspects of the clinical course and replacement therapy peculiarities in a patient with autoimmune polyglandular syndrome type 1: a clinical case
title_full Special aspects of the clinical course and replacement therapy peculiarities in a patient with autoimmune polyglandular syndrome type 1: a clinical case
title_fullStr Special aspects of the clinical course and replacement therapy peculiarities in a patient with autoimmune polyglandular syndrome type 1: a clinical case
title_full_unstemmed Special aspects of the clinical course and replacement therapy peculiarities in a patient with autoimmune polyglandular syndrome type 1: a clinical case
title_short Special aspects of the clinical course and replacement therapy peculiarities in a patient with autoimmune polyglandular syndrome type 1: a clinical case
title_sort special aspects of the clinical course and replacement therapy peculiarities in a patient with autoimmune polyglandular syndrome type 1 a clinical case
topic autoimmune polyglandular syndrome type 1
aire
autoimmune regulator gene
primary adrenal insufficiency
clinical case
adherence to treatment
url https://almclinmed.ru/jour/article/viewFile/17234/1696
work_keys_str_mv AT mariagpavlova specialaspectsoftheclinicalcourseandreplacementtherapypeculiaritiesinapatientwithautoimmunepolyglandularsyndrometype1aclinicalcase
AT olgaogolounina specialaspectsoftheclinicalcourseandreplacementtherapypeculiaritiesinapatientwithautoimmunepolyglandularsyndrometype1aclinicalcase
AT tatyanabmorgunova specialaspectsoftheclinicalcourseandreplacementtherapypeculiaritiesinapatientwithautoimmunepolyglandularsyndrometype1aclinicalcase
AT natalyavlikhodey specialaspectsoftheclinicalcourseandreplacementtherapypeculiaritiesinapatientwithautoimmunepolyglandularsyndrometype1aclinicalcase
AT marinafkalashnikova specialaspectsoftheclinicalcourseandreplacementtherapypeculiaritiesinapatientwithautoimmunepolyglandularsyndrometype1aclinicalcase
AT aleksandrgfarmanov specialaspectsoftheclinicalcourseandreplacementtherapypeculiaritiesinapatientwithautoimmunepolyglandularsyndrometype1aclinicalcase
AT tamrikodkhazaliya specialaspectsoftheclinicalcourseandreplacementtherapypeculiaritiesinapatientwithautoimmunepolyglandularsyndrometype1aclinicalcase
AT valentinvfadeev specialaspectsoftheclinicalcourseandreplacementtherapypeculiaritiesinapatientwithautoimmunepolyglandularsyndrometype1aclinicalcase